Implementation, Innovation, and Learnings from a two-year international Community of Practice (CoP) on Leadership Development in Fragility Fracture Management



Suzanne Murray¹, Bente Langdahl², Enrique Casado³, Keyla Brooks⁴, Cesar Libanati⁵, Livio Di Lecce⁶, Patrice Lazure¹ $\left\langle \frac{1}{2} \right\rangle$


1. AXDEV Group Inc., Brossard, Quebec, Canada. 2. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. 3. Department of Rheumatology, University Hospital Parc Taulí, I3PT Research Institute, Sabadell, Barcelona, Spain. 4. UCB Pharma., Smyrna, Georgia, United States. 5. UCB Pharma., Brussels, Belgium 6 UCB Pharma., Milano, Lombardy, Italy

- evolving environment
- functioning
- - practices.

- settings

- towards improving their leadership competencies.

- structured interviews, observations, forum discussions)



Funding: This study was financially supported by education research funds from UCB Pharma and Amgen Inc. Acknowledgements: The authors acknowledge the support provided by Michelle Mackechnie (UCB), Heather Pengelley and the AXDEV team (including Bethany Schowengerdt, Monica Augustyniak, Olivier Jacob); The authors thank all physicians who participated in the Community of Practice. Author Disclosures: SM is CEO and Founder of AXDEV Global Inc. and AXDEV Global Inc. and Gedeon-Richter, and has received honoraria for lectures from Amgen, UCB, and Eli Lilly. EC has received consulting fees or speaker remuneration from Eli Lilly, Amgen, UCB, Rubió, Theramex, Gebro, Italfármaco, Gedeon-Richter, STADA, Bayer and GP-Pharma. KB, CL, LL are employees of UCB. PL is an employee of AXDEV Group Inc.

